CCM
HRMY icon

CAAS Capital Management’s Harmony Biosciences HRMY Stock Holding History

CAAS Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,000
Closed -$203K – 866
2020
Q3 		$203K Buy
+6,000
New +$219K ﹤0.01% 438

Other funds holding HRMY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAAS Capital Management's HRMY Position: Q4 2020 in Review

CAAS Capital Management sold out of Harmony Biosciences (HRMY) in Q4 2020, closing a stake of 6,000 shares — an estimated $203K sold.

CAAS Capital Management first reported a position in HRMY in Q3 2020 and held it in 1 quarter. The position peaked at $203K in Q3 2020. 59 funds tracked by Wall St. Rank hold HRMY as of Q4 2020.

  • CAAS Capital Management reported no remaining Harmony Biosciences position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 6,000 Harmony Biosciences shares in Q4 2020, an estimated $203K.
  • CAAS Capital Management first reported a position in Harmony Biosciences in Q3 2020 and held it in 1 quarter.
  • CAAS Capital Management's Harmony Biosciences position peaked at $203K in Q3 2020.
  • 59 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.